Equities analysts expect that Catalent (NYSE:CTLT) will announce earnings per share (EPS) of $0.60 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Catalent’s earnings, with estimates ranging from $0.58 to $0.64. Catalent posted earnings of $0.65 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 7.7%. The firm is expected to report its next earnings report on Monday, August 27th.
According to Zacks, analysts expect that Catalent will report full year earnings of $1.68 per share for the current fiscal year, with EPS estimates ranging from $1.64 to $1.73. For the next year, analysts anticipate that the firm will post earnings of $1.90 per share, with EPS estimates ranging from $1.72 to $1.97. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Catalent.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, May 1st. The company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.06. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The firm’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 earnings per share.
NYSE:CTLT traded up $1.28 on Thursday, reaching $41.54. The company’s stock had a trading volume of 783,100 shares, compared to its average volume of 830,790. Catalent has a 12-month low of $33.42 and a 12-month high of $47.87. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53. The company has a market capitalization of $5.29 billion, a P/E ratio of 30.77, a P/E/G ratio of 2.11 and a beta of 1.50.
Several hedge funds and other institutional investors have recently made changes to their positions in CTLT. Summit Trail Advisors LLC boosted its position in shares of Catalent by 2,021.9% in the 1st quarter. Summit Trail Advisors LLC now owns 103,210 shares of the company’s stock valued at $103,000 after purchasing an additional 98,346 shares during the period. Point72 Asia Hong Kong Ltd boosted its position in shares of Catalent by 35,700.0% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 3,938 shares of the company’s stock valued at $162,000 after purchasing an additional 3,927 shares during the period. Quantbot Technologies LP purchased a new stake in Catalent during the 1st quarter valued at approximately $229,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in Catalent during the 4th quarter valued at approximately $242,000. Finally, Zeke Capital Advisors LLC purchased a new stake in Catalent during the 1st quarter valued at approximately $289,000. 99.52% of the stock is owned by hedge funds and other institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.